We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -0.71% | 6.95 | 16:05:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.00 | 6.85 | 7.00 | 6.95 | 7.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 30/12/2024 15:44 by gtc1508 Tipped today:“3. Fusion Antibodies (FAB): 7p Target 15p After some three years with its shares in the doghouse, made worse by the post pandemic hangover for biotechs, we have seen the FAB phoenix rise from the ashes. The driver in the recent past has been the prospect of what the stock market is very keen on, non-dilutive funding. In this instance, there is the prospect of approximately £1 million of direct funding for research & development initiatives, and access to up to £5 million of capital equipment. All of this coupled by the way that at the interim stage as reported in November FAB revenue had more than doubled, means that fans of the company are looking at a situation where 2025 could be a pivotal year. Before all the good news this autumn as recently as a year ago the shares were trading at 9p, and therefore one would expect this to be easily beaten in Q1 2025.” [...] |
Posted at 20/12/2024 22:29 by cbeadle The valuation for FAB is completely and fundamentally wrong. gtc1508 and troutisout great points. Very rarely shares 10 bag or more almost within days, FAB is in that category of possibility. I wouldn’t want to be out, much less short 😂. I think 65p is a fairer valuation than 6.5p . Holding tight! |
Posted at 17/12/2024 06:37 by lfdkmp Have just sent the following message to FAB - will be interesting to see if, and how quickly, the slides and presentations get amended."Having researched and witnessed FAB presentations I am excited by your prospects and am now a significant shareholder. At the risk of being considered pedantic, FAB is "certified" to ISO 9001, not "accredited" to ISO 9001. The people who are "accredited" are the certification bodies (eg BSI, Lloyds Registrar, NQA etc). I used to work for one of these. Some might consider the distinction to be a moot point, but given the nature of FAB operations and business environment, you would not want to be perceived by potential or existing clients as being imprecise or tolerant of lack of exactitude." |
Posted at 13/12/2024 08:48 by thiopia If GHO Capital made 10x there money on FairJourney why not re-invest some of that into FAB and do it again ?I don't think FAB can stay at these silly levels for long if the underlying business is seeing an upturn and there are smart cashed up investors in antibody CROs ready and willing to put capital to work |
Posted at 12/12/2024 19:45 by thiopia for infoGheko Posts: 991 Price: 6.90 Strong Buy Webinar Today 18:15 Great webinar presentation. A few takeaways for me. 1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard. 2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price! 3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins. 4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news. 5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’. Very happy with my investment and adding more tomorrow. |
Posted at 12/12/2024 19:36 by thiopia some snippets from ShareScope webinarGheko Posts: 991 Price: 6.90 Strong Buy Webinar Today 18:15 Great webinar presentation. A few takeaways for me. 1. The work around Optimal and Optiphage platforms. They could potentially be licensed to every biotech company in THE WORLD!! Hello, all aboard. 2.slip of the tongue when talking about the work with US National Cancer Institute. I got sense that they know it is a done deal. If that announcement comes then add then add an immediate 0 to the share price! 3. As a result of the grant funding where FAB are not paying for the equipment or upkeep they can look to grow margins. 4. When asked about potential news in next 3-6 months naturally very coy but I sensed he looking forward to lots of news. 5. Final comment was the grant gives FAB quote ‘a remarkable opportunity’. Very happy with my investment and adding more tomorrow. |
Posted at 12/12/2024 04:41 by imjustdandy It's all coming together for FAB. Looking forward to the CEO update this evening. This is FABs moment. |
Posted at 09/12/2024 17:03 by cbeadle The difference in value of Absci and FJ Bio , probably the comparator benchmark companies that you are thinking of is completely insane. If FAB was priced at £1 tomorrow it would still just be at a small fraction of their valuations, and there’s no especial evidence that either are way in front of FAB. Of course they have the current advantage that they could raise capital more easily by dilution than FAB, but the gap must surely close sometime soon. Today a good 10%+ day, signs that last week’s RNS has kindled interest in Fusion |
Posted at 05/12/2024 20:25 by thiopia There was no forewarning of this £6m of funds + benefits in kind from #FAB as far as I am aware.Does make you wonder what else they are working on. What they have in the pipeline with regard to milestones/royalties from previous IP assets Let alone the new platforms and in particular the US NCI relationship Been just over a year into the 2 year relationship. Will be interesting to see if there is a substantial update to mark the 1 year anniversary ? Maybe next week's Investor Presentation ? 28 November 2023 Fusion Antibodies plc OptiMAL® collaboration agreement Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has signed a collaboration agreement (the "Agreement") with the National Cancer Institute ("NCI") for the use of OptiMAL® in the discovery of novel antibodies against targets selected by NCI. Under the terms of the Agreement, Fusion will provide access to the OptiMAL® technology to NCI for deployment against an agreed number of targets, being primarily cancer targets, over a period of up to two years, in order to develop potential therapeutic antibodies against the selected targets. The parties will work together to ensure successful validation of the OptiMAL® technology and jointly publish any results from the collaboration. The validation will be run at NCI's laboratories by their staff and antibodies identified pursuant to the Agreement would be retained by NCI. NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Adrian Kinkaid, CEO of Fusion, commented: "At the time of our fundraise in May, we said that we would be seeking the support of third parties to continue to progress the delivery of OptiMAL®. We are delighted to have been able to secure a partner with the expertise of NCI to provide validation to the technology without Fusion being required to commit significant resource to the project." Mitchell Ho, Ph.D., Deputy Chief, Laboratory of Molecular Biology and Director of the Antibody Engineering Program, Center for Cancer Research, NCI commented: "NCI will test the OptiMAL® platform for the discovery of novel antibodies to cancer targets and also SARS-CoV-2. We have a particular interest in Mammalian Cell Display as a discovery engine and look forward to using this in NCI." Richard Buick, CSO of Fusion, commented: "The expertise and experience of Dr. Ho and his colleagues make NCI an ideal partner for validation of the Optimal® library and mammalian cell display technology. I look forward to the collaboration and working closely with the National Cancer Institute." |
Posted at 02/7/2024 19:10 by jaknife troutisout,I have DM'd you the Allenby broker forecasts. But my apologies my wording was imprecise, "in 20024" should be "in the year to 31 Dec 2024", there are no forecasts available beyond that. What words/numbers in the 30 April 2024 Year-end trading statement make you think that "FAB have turned a corner"? I note: "Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues" However: 1. This was the first time that FAB published a number for their pipeline so it's impossible to tell if this represents an improvement on the prior period and hence evidence of having "turned a corner"? 2. The gross margin in the year to 31 March 2023 was 19.8% and admin costs are in the ball park of £3m per annum. That means that FAB has to get to a revenue of c. £15m in order to just break even. Ie: (£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000Profit for the period £ 0 I have assumed a 20% gross profit margin to keep the numbers simple. If FAB don't get to a revenue of £15m then they will make a loss in the year to 31 March 2025. Furthermore, if FAB don't get to half of that revenue number (£7,500k) then FAB will burn through their current cash and need to raise funds again. What forecast full-year revenue for 2025 do you infer from the 30 April 2024 Year-end trading statement? JakNife |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
